AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05702944 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Phenoxybenzamine
Description: Patients in sham comparator group take a phenoxybenzamine at least 2 to 5 weeks before surgery. If blood pressure is more than 130/80 mmHg in the sitting position, the patient will take a more amount of phenoxybenzamine. If blood pressure is less than 90 mmHg in the standing position, the patient will take a less amount of phenoxybenzamine. In active comparator group, there is no drug to be taken.
Study NCT04440241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regenerative treatment periimplantitis
Description: Full thickness buccal and lingual flaps will be performed. After debridement of the defect using hand and ultrasonic instruments and implant surface decontamination using titanium brushes (TiBrush®) and saline Regenerative treatment will be performed only in the intrabony component of type 1 peri-implant defects. Guided bone regeneration using a bone substitute (Bio-oss®) and a resorbable membrane (bio-gide®) will be performed in the intrabony and dehiscenses areas of the defect.~The surgeon will be blinded to the assignment of treatment until it is time to close the flaps.
Study NCT06335940 — intervention group
Intervention type: OTHER
Intervention: Videoregulation
Description: To encourage the use of video-regulation, several measures will be taken to reinforce its use as much as possible:~* Posters visible to all in the dispatch room.~* Regular mailings to all dispatching physicians.~* On-site presence of interns and the study investigator to help doctors who are not used to video-regulation to get to grips with the computer tool.~* Involvement of ARMs to remind doctors to use video-regulation.
Study NCT05738889 — intervention group
Intervention type: DEVICE
Intervention: Fixed lingual retainers applied with Bis-GMA containing composite
Description: Bonding materials of fixed lingual retainers applied with Bis-GMA containing composite
Study NCT05738889 — intervention group
Intervention type: DEVICE
Intervention: Fixed lingual retainers applied with Bis-GMA-free composite
Description: Bonding materials of fixed lingual retainers applied with Bis-GMA-free composite
Study NCT05738889 — intervention group
Intervention type: DEVICE
Intervention: Vacuum-formed retainers
Description: vacuum-forming machine and vacuum formed plates
Study NCT05738889 — intervention group
Intervention type: DEVICE
Intervention: Hawley retainers
Description: Acrylic based hawley retainers
Study NCT06532071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]CBP8
Description: Participants will receive a single intravenous injection of up to 350 MBq of \[68Ga\]CBP8
Study NCT06532071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoterate Meglumine
Description: Participants will receive a single intravenous injection of 0.05 mmol/kg gadoterate meglumine during DCE-MRI
Study NCT06173843 — intervention group
Intervention type: OTHER
Intervention: PFAS / heavy metal testing, exposures
Description: PFAS / heavy metal concentrations, exposure survey
Study NCT06488001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Description: Pantoprazole 40mg given the night before surgery, 2 hours prior to surgery, and the evening after surgery.
Study NCT06488001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given the night before surgery, 2 hours prior to surgery, and the evening after surgery.
Study NCT06413771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Description: Letrozole pretreatment during ovarian stimulation with gonadotropins, in intrauterine insemination cycles.
Study NCT06413771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin
Description: Ovarian stimulation with gonadotropins, in intrauterine insemination cycles.
Study NCT05263843 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biological markers of myocardial fibrosis
Description: Blood sample for measurements of NET activation and collagen biomarkers
Study NCT05129709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Health Priorities Identification Program
Description: The web-based My Health Priorities Identification Program may improve values solicitation and operationalization skills in primary care, but has not been optimized for AAs with MCCs and their FCGs. The Program is a facilitator-led evidence- and values-based care communication model for patients, clinicians, and caregivers that has reduced patient-reported treatment burden by aligning value-based priorities with treatment. The web-based program assists patients in identifying their health priorities as they complete t four online modules that help them to identify specific and actionable health goals and preferences. The final result can be printed and brought to the clinic or uploaded to the Electronic Medical Record to inform subsequent healthcare decision making. Unrecognized cultural preferences of AAs, including the important role of R/S beliefs and family-centered values, can interfere with adequate healthcare communication resulting in healthcare disparities and inequities.
Study NCT06735924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-oxalate fixed diet
Description: Ingestion of a low-oxalate (\< 60 mg/day) , normal calcium (800-1200 mg/d) eucaloric diet for 5 days
Study NCT06739928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome (II) combined with adebrelimab and carboplatin
Description: Irinotecan liposome (II) + adebrelimab + carboplatin
Study NCT05427630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC ~2.5%
Description: Cannabis flower containing THC \~2.5%
Study NCT05427630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC ~5%
Description: Cannabis flower containing THC \~5%
Study NCT05427630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC ~10%
Description: Cannabis flower containing THC \~5%
Study NCT05427630 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Cannabis
Description: Cannabis flower from which the THC and CBD have been extracted
Study NCT05465681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20013 for injection；dexamethason
Description: HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy.~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy
Study NCT06034730 — intervention group
Intervention type: DEVICE
Intervention: Portable GC device for brath analysis
Description: Patients were asked to orally exhale 1-2 L breath into a 5 L Tedlar bag via a one-way mouthpiece and Nafion filter for moisture removal, as shown in Figure 1B. The process usually takes about a few minutes. The breath analysis took place either in-situ immediately after the breath sample collection or within 24 h of breath collection. The Tedlar bags were stored under ambient condition until analyzed. During the breath analysis, the Tedlar bag was connected to the sampling port of the portable GC (Figure 1C). Approximately 350 mL of breath was pulled from the Tedlar bag into the GC for analysis. The GC operation was controlled using LabView via a laptop. The total assay time was 30 min, including 5 min of breath sampling time from the Tedlar bag at a flow rate of 70 mL/min (see the blue path in Figure 1A), 5 min of desorption/transfer time, 10 min of chromatographic separation time (see the orange path in Figure 1A), and 10 min of GC system cleaning time.
Study NCT04053153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise equipment (a musical instrument that is based on the Medical Didgeridoo)
Description: exercise equipment (a musical instrument that is based on the Medical Didgeridoo)
Study NCT04053153 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exercise equipment (a musical instrument that is based on the Medical Didgeridoo)
Description: exercise equipment (a musical instrument that is based on the Medical Didgeridoo)
Study NCT05717322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TENS
Description: apply TENS after orthognathic surgery
Study NCT05717322 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sham TENS
Description: apply non active TENS after orthognathic surgery
Study NCT06739928 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: etoposide combined with adebrelimab and carboplatin
Description: etoposide + adebrelimab + carboplatin
Study NCT06332638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 12.5mg
Description: Oral administration of one tablet of Tegoprazan 12.5mg twice daily for 14 days.
Study NCT06332638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegoprazan 25mg
Description: Oral administration of one tablet of Tegoprazan 25mg once daily for 14 days.
Study NCT06332638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine 20mg
Description: Oral administration of one tablet of Famotidine 20mg twice daily for 14 days.
Study NCT06516835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral fluid
Description: GNAK will be administered to the gastrointestinal tract with EN in the same volume.
Study NCT06516835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous fluid
Description: Undiluted EN will be given to the gastrointestinal tract. GNAK, in the same volume, will be administered intravenously.
Study NCT04949919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic training by a cycle ergometer and Biodex system 4 pro
Description: cyclic aerobic training in moderate-intensity and high-intensity interval training plus isokinetic resistance training prior to HD. 60 training sessions in 6 months.
Study NCT05634356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vocal-social reinforcement
Description: experimental manipulation of social reinforcement in response to vocalizations
Study NCT04460937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO
Study NCT04460937 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT06737692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised Aerobic Exercises: Conducted every two weeks, three days a week (on days 11-13 post-systemic treatment). The supervised aerobic exercises will consist of 20 minutes on a treadmill at a heart rate corresponding to 55-75% of the Karvonen formula. Warm-up and cool-down will be performed at 30-40% of the Karvonen heart rate for 5 minutes.~Supervised Resistance Exercises: Conducted every two weeks on consecutive days (days 11 and 13 post-systemic treatment).~Resistance training will involve 12 different exercises targeting major muscle groups, using body weight and resistance bands, at an effort level of 5-7 on the Borg scale, with 8-12 repetitions and 1-3 sets. The intensity will be progressively adjusted based on the individual's perceived exertion.~On weeks without supervised exercises, participants will follow a home exercise program that includes breathing exercises, walking for 20-30 minutes, and resistance exercises.
Study NCT05003245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection
Description: 0.05mL solution at a 4-week interval for intravitreal injection
Study NCT05003245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: 0.05mL solution at a 4-week interval for intravitreal injection
Study NCT04820985 — intervention group
Intervention type: OTHER
Intervention: Vaginal swab
Description: Vaginal flora swab 3 months before stimulation, at oocyte puncture, embryo transfer and beta-human chorionic gonadotropin dosing
Study NCT04820985 — intervention group
Intervention type: OTHER
Intervention: Blood test
Description: Blood sample to measure plasma dose of progesterone
Study NCT06463912 — intervention group
Intervention type: OTHER
Intervention: Does not apply
Description: A descriptive cross-sectional study will be carried out in the city of Armenia-Colombia. A total of 205 PWID, 18 years to 65 years old will be included. They will be selected through the implementation of the respondent-driven sampling (RDS).
Study NCT04817540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herzuma
Description: 8mg/kg IVF loading dose at first cycle -> 6mg/kg IVF at 2,3,4th cycle of each 21 day cycle
Study NCT06741241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth Promotora
Description: Intervention participants attend an eHealth promotora-delivered educational session. Activities include an icebreaker, the completion of a baseline survey, an introduction to cervical cancer using a video and slide presentation, a cervical cancer knowledge pretest/posttest, and a dialogue activity to explore possible barriers and solutions to health care access. Main topics included in the slide presentation are: female anatomy; cervical cancer etiology and disease progression by stage; cancer prevention including diet, exercise, safe sex, cancer screening; human papillomavirus (HPV) vaccine recommendations; Pap test preparations, procedure, screening interval; and information about where to receive a Pap test and seek more information about cervical cancer.
Study NCT06147375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus or Cyclosporine A
Description: The protocol of IS withdrawal:Week 1-4 take Tacrolimus (Tac) or Cyclosporine A (CsA) once daily for weeks. Week 5-8 medication reduction to taking Tac / CsA 4 times a week . Week 9-12 reduction to taking Tac/ CsA 3 times a week. Week 13-18 reduction to taking Tac / CsA 2 times a week . Week 19-24 reduction to taking Tac/ CsA once per week. Week 25, the recipients will stop taking Tac/ CsA.
Study NCT06741241 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eHealth Healthy Nutrition
Description: Control group participants attend an eHealth educational session on healthy nutrition. Activities include an icebreaker, the completion of a baseline survey, an introduction to healthy eating using a video and a slide presentation, a cervical cancer knowledge pretest/posttest, and a dialogue activity to explore benefits and challenges to healthy eating.
Study NCT06739018 — intervention group
Intervention type: OTHER
Intervention: pentacam scheimpflug tomography
Description: Pentacam tomography is not radiation-based. It uses Scheimpflug imaging, which involves a rotating camera that captures multiple images of the anterior segment of the eye. The system employs light-based technology to measure the front and back surfaces of the cornea, along with the anterior chamber and lens, creating a 3D model of the anterior eye structures.~it uses light instead of ionizing radiation (like X-rays), it is considered safe and non-invasive for routine use in ophthalmology.~* It was used to assess 23 parameters from topographic maps and 15 parameters from Belin-Ambrosio enhanced ectasia (BAD) display maps.~* Parameters included keratometry readings, anterior and posterior sagittal curvature, corneal thickness, anterior chamber volume, and several indices from the BAD display map.~* These parameters were analyzed to discriminate between keratoconus and high myopic astigmatism using Receiver Operating Characteristic (ROC) curves for diagnostic accuracy.
Study NCT05370417 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Use of fluoride toothpaste
Description: The participants received oral hygiene instructions - routine brushing twice per day with toothpaste containing 1000 ppm of fluoride. All participants received a toothbrush and toothpaste to ensure standardization. The aim of this intervention was to assess whether the participants' brushing technique would improve with desensitization.
Study NCT05370417 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of fluoride toothpaste
Description: The participants received oral hygiene instructions - routine brushing twice per day with toothpaste containing 1000 ppm of fluoride. All participants received a toothbrush and toothpaste to ensure standardization. The aim of this intervention was to assess whether the participants' brushing technique would improve with desensitization.
Study NCT05370417 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: For laser application, the following dosimetric parameters will be used:~Low level laser diode (infra red) wavelength 808nm with a power of 100mW. Three sessions: initial session, after 48 hours and after one month. LLL was applied to three perpendicular points in contact with the surface on the mesial vestibular and distal cervical faces and in the center of the occlusal face. An energy of 1 J was applied for 10 seconds at each point.
Study NCT05370417 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Simulated Laser Therapy
Description: The same application described in the laser therapy group will be simulated, with the device turned off.
Study NCT05370417 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sealant application
Description: A glass ionomer sealant will be applied to the occlusal surface of the first permanent molar.
Study NCT05370417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sealant application
Description: A glass ionomer sealant will be applied to the occlusal surface of the first permanent molar.
Study NCT05746455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation Skills Training (MST)
Description: MST is a weekly group-based skills training intervention that aims to improve knowledge about one's level and sources of motivation, the ability to monitor and regulate (understand and manage) motivation, so that one can better initiate and sustain goal-directed behavior.
Study NCT05065281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Training for health care professionals on how to identify and manage cases of elder abuse among their patients
Study NCT05362344 — intervention group
Intervention type: PROCEDURE
Intervention: Stool tests
Description: Non-invasive, stool-based tests for colorectal cancer screening.
Study NCT04510597 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cytoreductive Nephrectomy
Description: Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization
Study NCT04510597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Nephrectomy
Description: Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization
Study NCT04510597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Nivolumab 240 mg IV 1 q 2 weeks~OR~Nivolumab 480 mg IV 1 q 4 weeks~OR~Pembrolizumab 200 mg IV 1 q 3 weeks Axitinib 5 mg oral Daily BID~OR~Avelumab 10 mg/kg IV 1 q 2 weeks Axitinib 5 mg oral Daily BID
Study NCT04776798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping
Description: Tape applications will repeat twice per week, for 4 weeks.
Study NCT04776798 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Taping
Description: Tape applications will repeat twice per week, for 4 weeks.
Study NCT04594577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluispotter
Description: Fluispotter automated blood sampling system applied for venous blood sampling of 20 10 μL samples in a 20 hours sampling session.
Study NCT05435196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise
Description: The control group and the experimental group will receive the training with high-intensity interval exercise. For a period of 12 weeks both groups will participate in their exercise program, which will be supervised by the physiotherapist in charge of the study; different from the one who will carry out the randomization and the one who will perform the evaluations. Women will attend 3 times a week for an hour to the Hospital de especialidades to receive their exercise program in which they participated. Both groups will receive therapeutic education to encourage adherence and self-management, which include aspects such as flexibility, musculoskeletal pain, physical performance, quality of life focused on physical and mental health, etc.
Study NCT05435196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: The control group and the experimental group will receive the training with high-intensity interval exercise. For a period of 12 weeks both groups will participate in their exercise program, which will be supervised by the physiotherapist in charge of the study; different from the one who will carry out the randomization and the one who will perform the evaluations. Women will attend 3 times a week for an hour to the Hospital de especialidades to receive their exercise program in which they participated. Both groups will receive therapeutic education to encourage adherence and self-management, which include aspects such as flexibility, musculoskeletal pain, physical performance, quality of life focused on physical and mental health, etc.
Study NCT03442491 — intervention group
Intervention type: PROCEDURE
Intervention: Hayman's Haemostatic Suture
Description: After the uterus is exteriorised, bimanual compression is applied to check whether this stopped the bleeding, before the suture is applied. A number 2 polyglactin suture on a straight needle is used to transfix the uterus from front to back, just above the reflection of the bladder, and is then tied above the fundus of the uterus, while an assistant applies bimanual compression.
Study NCT05373615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
Study NCT05910164 — intervention group
Intervention type: DEVICE
Intervention: PELGRAZ prefilled syringe or PELGRAZ prefilled pen
Description: PELGRAZ prefilled syringe or PELGRAZ prefilled pen https://www.ema.europa.eu/en/medicines/human/EPAR/pelgraz